1985Journal of Veterinary Pharmacology and TherapeuticsRequires access

Effect of probenecid on the pharmacokinetics of cefotaxime in sheep

V. H. GUERRINI, L. J. FILIPPIGH, P. B. English, G. R. CAO, David W. A. Bourne

Open publisher page 7 citations

Abstract

Guerrini, V.H., Filippich, L.J., English, P.B., Cao, G.R. &: Bourne, D.W.A. Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. J. vet. Pharmacol. Therap. 8, 38–46. The effect of probenecid given by intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection on the pharmacokinetics of cefotaxime was studied in six Merino ewes. When given intravenously, probenecid increased significantly (P < 0.05) the plasma half‐life of cefotaxime three‐fold (to 0.94 ± 0.32 h) and the area under the curve (AUG) approximately two‐fold (to 41.1 ± 16.8 μg.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 ± 0.191 1/h/kg). When given with probenecid intravenously, renal clearance (ClR), volume of the central compartment (VC), volume of distribution steady slate (Vd(ss)). and the amount excreted in urine unchanged did not alter significantly. When given by i.m. injection, probenecid and cefotaxime were well tolerated and cefotaxime was well absorbed (101 ± 45%). When given by s.c. injection, only 40 ± 25% cefotaxime was absorbed. When given intramuscularly or subcutaneously, probenecid appeared to reduce the ClB and ClR of cefotaxime, probably because plasma probenecid concentrations are prolonged. Probenecid did not appear to affect the distribution of cefotaxime. Dr D.W.A. Bourne, Department of Pharmacy, University of Queensland, St Lucia, QLD 4067, Australia.

About this research paper

What this paper is about

Guerrini, V.H., Filippich, L.J., English, P.B., Cao, G.R. &: Bourne, D.W.A. Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. J. vet. Pharmacol. Therap. 8, 38–46. The effect of probenecid given by intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection on the pharmacokinetics of cefotaxime was studied in six Merino ewes. When given intravenously, probenecid increased significantly (P < 0.05) the plasma half‐life of cefotaxime three‐fold (to 0.94 ± 0.32 h) and the area under the curve (AUG) approximately two‐fold (to 41.1 ± 16.8 μg.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 ± 0.191 1/h/kg). When given with probenecid intravenously, renal clearance (ClR), volume of the central compartment (VC), volume of distribution steady slate (Vd(ss)). and the amount excreted in urine unchanged did not alter significantly. When given by i.m. injection, probenecid and cefotaxime were well tolerated and cefotaxime was well absorbed (101 ± 45%). When given by s.c. injection, only 40 ± 25% cefotaxime was absorbed. When given intramuscularly or subcutaneously, probenecid appeared to reduce the ClB and ClR of cefotaxime, probably because plasma probenecid concentrations are prolonged. Probenecid did not appear to affect the distribution of cefotaxime. Dr D.W.A. Bourne, Department of Pharmacy, University of Queensland, St Lucia, QLD 4067, Australia.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Guerrini, V.H., Filippich, L.J., English, P.B., Cao, G.R. &: Bourne, D.W.A. Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. J. vet. Pharmacol. Therap. 8, 38–46. The effect of probenecid given by intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection on the pharmacokinetics of cefotaxime was studied in six Merino ewes. When given intravenously, probenecid increased significantly (P < 0.05) the plasma half‐life of cefotaxime three‐fold (to 0.94 ± 0.32 h) and the area under the curve (AUG) approximately two‐fold (to 41.1 ± 16.8 μg.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 ± 0.191 1/h/kg). When given with probenecid intravenously, renal clearance (ClR), volume of the central compartment (VC), volume of distribution steady slate (Vd(ss)). and the amount excreted in urine unchanged did not alter significantly. When given by i.m. injection, probenecid and cefotaxime were well tolerated and cefotaxime was well absorbed (101 ± 45%). When given by s.c. injection, only 40 ± 25% cefotaxime was absorbed. When given intramuscularly or subcutaneously, probenecid appeared to reduce the ClB and ClR of cefotaxime, probably because plasma probenecid concentrations are prolonged. Probenecid did not appear to affect the distribution of cefotaxime. Dr D.W.A. Bourne, Department of Pharmacy, University of Queensland, St Lucia, QLD 4067, Australia.

Key concepts: Probenecid, Cefotaxime, Pharmacokinetics, Volume of distribution, Chemistry, Pharmacology, Distribution (mathematics), Urine

Related papers

Back to paper searchBrowse research topicsOriginal source
Effect of probenecid on the pharmacokinetics of cefotaxime in sheep — Research Paper | ScholarLens